Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This clinical trial is an investigator-initiated multicenter, open, prospective clinical study in order to explore the efficacy and safety of rituximab plus zanubrutinib and lenalidomide in relapsed and refractory diffuse large B cell lymphoma.
Epistemonikos ID: be0893dbfc16feb3738de7e02916b6b2978e8bf8
First added on: May 13, 2024